A US district court ruled in favor of NeoGenomics, invalidating two of Natera's patents related to minimal residual disease (MRD) detection assays. This ruling allows NeoGenomics to market its Radar ST assay freely in the US and could accelerate innovation and competition in cancer diagnostics. NeoGenomics shares surged following the decision, highlighting market optimism. The ruling does not impact a separate Natera patent involved in related litigation.